Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Neonc Technologies Inc. maintains 4 pending office actions within the Biotechnology & Pharmaceuticals sector. These matters are distributed across 4 distinct examiners and 4 distinct art units. This distribution indicates that each pending action is being handled by a unique examiner in a unique art unit, reflecting a spread of technical subject matter within the portfolio. Such a wide distribution across 4 art units suggests that the company's research and development may cover several specialized niches within the broader biotechnology field.
The busiest examiner for the company is LEE, HOI YAN NMN, who is currently managing 1 pending office action. Because the total number of pending office actions is 4 and there are 4 distinct examiners, each examiner holds a matching portion of the workload. This distribution across the examiners suggests that prosecution strategies may need to be tailored to the specific tendencies of each individual official. The lack of concentration under a single examiner means that no single prosecution outcome will determine the status of the entire pending portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, HOI YAN NMN | 1 | 38.4% | +75.9% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17251452 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RODRIGUEZ, RAYNA B | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248733 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | LEE, HOI YAN NMN | 134d overdue |
| 18001082 | COMPOSITIONS AND METHODS FOR DELIVERING POLYNUCLEOTIDES | ZARA, JANE J | 118d overdue |
| 17251452 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RODRIGUEZ, RAYNA B | 55d |
| 17762878 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1637 | 1 |
| 1627 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18248733 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | LEE, HOI YAN NMN | 1693 | §103DP | Non-Final OA | 134d overdue | Pending | Apr 12, 2023 |
| 18001082 | COMPOSITIONS AND METHODS FOR DELIVERING POLYNUCLEOTIDES | ZARA, JANE J | 1637 | §103 | Final Rejection | 118d overdue | Pending | Dec 08, 2022 |
| 17762878 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RAO, PADMAJA S | 1627 | §103DP | Non-Final OA | — | Pending | Mar 23, 2022 |
| 17251452 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | RODRIGUEZ, RAYNA B | 1628 | §102§103Other | Non-Final OA | 55d | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial